Since skin tone, pigmentation depth, and treatment choice vary from person to person, dermatologists first assess the skin before recommending a customized plan
The Injection (Subcutaneous) - Dosing: Once weekly - Bioavailability: ~100% (bypasses GI tract) - Weight loss in trials: Up to 22% at 36 weeks - Best for: Patients seeking maximum efficacy, comfortable with self-injection The Pill (Oral) - Dosing: Once daily (taken on an empty stomach, similar to Rybelsus) - Bioavailability: Lower than SC (relies on SNAC absorption technology) - Weight loss in trials: Up to 13.1% at 12 weeks (Phase 1 short duration) - Best for: Injection-averse patients, early treatment, maintenance, broader access The oral formulation will almost certainly deliver less weight loss than the subcutaneous version at equivalent treatment durations
Liver Histology At the end of treatment, histological analysis was performed to evaluate hepatocellular steatosis and fibrosis
Based on clinical trial data, weight tends to return and appetite may shift after stopping though how much varies considerably between individuals and by the specific medication involved
Although the active domain of GPx5 lacks selenocysteine, it retains antioxidant properties [18]